Locally Advanced and Recurrent Rectal Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 1220

Special Issue Editor


E-Mail Website
Guest Editor
Department of Digestive Surgery, Rouen University Hospital, F-76031 Rouen, France
Interests: colorectal surgery; rectal cancer; locally recurrent rectal cancer; multivisceral resection; peritoneal metastasis; HIPEC; medical ethics; quality of life
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the Special Issue “Locally Advanced and Recurrent Rectal Cancer” (https://0-www-mdpi-com.brum.beds.ac.uk/journal/cancers/special_issues/Recurrent_Rectal_Cancer).

Treatment for patients with locally advanced and recurrent rectal cancer differs significantly from patients with rectal cancer restricted to the mesorectum. The adequate preoperative imaging of the pelvis is therefore important for identifying those patients that are candidates for multimodality treatment, including preoperative chemoradiation protocols, intraoperative radiotherapy, and extended surgical resections. A lot of effort should be made to select patients with these advanced tumors for treatment in specialized referral centers. This has been shown to reduce morbidity as well as mortality and improve long-term survival rates. Not only volume, but a multidisciplinary team, including a radiation oncologist, urologist, surgical oncologist, plastic surgeon, and gynecologist, is also of importance in these surgical procedures. Traditionally, peritoneal carcinomatosis, high sacral involvement, the encasement of external iliac vessels, the invasion of the sciatic notch, bilateral ureteral obstruction with bilateral hydronephrosis, and the presence of gross lower limb edema (in addition to unresectable distant metastases) were considered absolute contraindications to pelvic exenteration surgery. Many of these dogmas have been challenged as exenteration centers around the world extend the traditional boundaries of resection.

The past two to three decades, however, have seen the increasing acceptance of pelvic exenteration for patients with isolated locally recurrent rectal cancer because of the number of studies demonstrating reduced operative mortality and improved overall survival in large case series as well as quality of life outcomes. Long-term survivors after pelvic exenteration for local recurrence have a comparable quality of life to patients who had primary rectal cancer. Several studies have demonstrated that the quality of life of pelvic exenteration patients was preserved compared to patients who underwent palliative treatment. These radical surgical approaches have previously been controversial in the surgical literature, but are no longer controversial in view of the strong and overwhelming evidence that suggests that the R0 resection margin is the main predictor of long-term survival.

The aim of this Special Issue is to provide an update on articles focused on the evolution and future of multimodal therapy for locally recurrent rectal cancer.

Prof. Dr. Jean-Jacques Tuech
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rectal cancer
  • rectal imaging
  • chemoradiation
  • advanced rectal cancer
  • locally recurrent rectal cancer
  • multimodal treatment
  • neoadjuvant chemoradiation
  • prehabilitation
  • pelvic exenteration
  • multivisceral resection
  • pelvic reconstruction
  • urinary reconstruction
  • rehabilitation
  • quality of life
  • palliative surgery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2850 KiB  
Article
Late Local Recurrence after Neoadjuvant Therapy and Radical Resection for Locally Advanced Rectal Cancer
by Adrian Salega, Marina Münch, Philipp Renner, Klaus-Peter Thon, Wolfgang Steurer, Dina Mönch, Jana Koch, Annika Maaß, Hans Jürgen Schlitt, Marc-Hendrik Dahlke and Tobias Leibold
Cancers 2024, 16(2), 448; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16020448 - 20 Jan 2024
Viewed by 961
Abstract
Neoadjuvant radiochemotherapy (RCT) and lately total neoadjuvant therapy (TNT) improved local recurrence rates of rectal cancer significantly compared to total mesorectal excision (TME) alone. Yet the occurrence and impact of late local recurrences after many years appears to be a distinct biological problem. [...] Read more.
Neoadjuvant radiochemotherapy (RCT) and lately total neoadjuvant therapy (TNT) improved local recurrence rates of rectal cancer significantly compared to total mesorectal excision (TME) alone. Yet the occurrence and impact of late local recurrences after many years appears to be a distinct biological problem. We included n = 188 patients with rectal cancer after RCT and radical resection in this study; n = 38 of which had recurrent disease (sites: local (8.0%), liver (6.4%), lung (3.7%)). We found that 68% of all recurrences developed within the first two years. Four patients, however, experience recurrence >8 years after surgery. Here, we report and characterize four cases of late local recurrence (10% of patients with recurrent disease), suggesting that neoadjuvant therapy in principle delays local recurrence. Full article
(This article belongs to the Special Issue Locally Advanced and Recurrent Rectal Cancer (2nd Edition))
Show Figures

Figure 1

Back to TopTop